

September 11, 2008

**October ICD-9-CM and HCPCS code updates**

The National Center for Health Statistics (NCHS) and the Centers for Medicare & Medicaid Services (CMS) have released the 2009 ICD-9-CM (International Classification of Diseases, ninth revision, Clinical Modification) updates. There are also several added and revised HCPCS\* (CPT and Level II) codes that are effective October 1, 2008.

**Submitting**

Blue Cross and Blue Shield of Minnesota and Blue Plus will accept all added ICD-9-CM and HCPCS codes effective on October 1, 2008.

Because there is no grace period for invalid or discontinued codes, if a discontinued/invalid code is submitted with a date of service of October 1, 2008 or later, the claim will be rejected. Likewise, added codes will be rejected if submitted with a date of service before October 1.

**Ordering 2009 ICD-9-CM books**

ICD-9-CM manuals are not available from Blue Cross. ICD-9-CM manuals are available from several sources, such as the American Medical Association (AMA), Ingenix, or major bookstores. To view the ICD-9-CM codes that are effective October 1, 2008, go to

<http://www.cdc.gov/nchs/dataawh/ftpserv/ftpicd9/ftpicd9.htm>

**HCPCS code list**

HCPCS and CPT manuals are generally only published once a year; however, quarterly revisions may be issued by CMS and/or the AMA. The codes listed in this bulletin are effective October 1, 2008 unless otherwise specified.

**Questions?**

If you have any questions, please contact provider service at **(651) 662-5200** or toll free at **1-800-262-0820**.

**ADDED CODES:**

C9243	Injection, bendamustine hcl, 1 mg
C9244	Injection, regadenoson, 0.4 mg
C9359	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Putty, Integra OS Osteoconductive Scaffold Putty), per 0.5 cc
C9898	Radiolabeled product provided during a hospital inpatient stay
S2118	Metal-on-metal total hip resurfacing, including acetabular and femoral components
S2270	Insertion of vaginal cylinder for application of radiation source or clinical brachytherapy (report separately in addition to radiation source delivery)
S3860	Genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes
S3861	Genetic testing, sodium channel, voltage-gated, type v, alpha subunit (scn5a) and variants for suspected brugada syndrome
S3862	Genetic testing, family-specific ion channel analysis, for blood-relatives of individuals (index case) who have previously tested positive for a genetic variant of a cardiac ion channel syndrome using either one of the above test configurations or confirmed results from another laboratory

0520F	Radiation dose limits to normal tissues* established prior to* the initiation of a course of 3D conformal radiation for a minimum of two* tissues/organs (ONC) <sup>1</sup>
0575F	HIV RNA control plan of care, documented (HIV) <sup>5</sup>
1220F	Patient screened for depression (SUD) <sup>5</sup>
3250F	Specimen biopsy site other than anatomic location of primary tumor (eg, liver biopsy, lymph node biopsy) (PATH) <sup>1</sup>
3370F	AJCC Breast Cancer Stage 0, documented (ONC) <sup>1</sup>
3372F	AJCC Breast Cancer Stage I: T1mic, T1a or T1b (tumor size ≤ 1 cm), documented (ONC) <sup>1</sup>
3374F	AJCC Breast Cancer Stage I: T1c (tumor size > 1cm to 2 cm), documented (ONC) <sup>1</sup>
3376F	AJCC Breast Cancer Stage II, documented (ONC) <sup>1</sup>
3378F	AJCC Breast Cancer Stage III, documented (ONC) <sup>1</sup>
3380F	AJCC Breast Cancer Stage IV, documented (ONC) <sup>1</sup>
3382F	AJCC colon cancer, Stage 0, documented (ONC) <sup>1</sup>
3384F	AJCC colon cancer, Stage I, documented (ONC) <sup>1</sup>
3386F	AJCC colon cancer, Stage II, documented (ONC) <sup>1</sup>
3388F	AJCC colon cancer, Stage III, documented (ONC) <sup>1</sup>
3390F	AJCC colon cancer, Stage IV, documented (ONC) <sup>1</sup>
3500F	CD4+ cell count or CD4+ cell percentage documented as performed (HIV) <sup>5</sup>
3502F	HIV RNA viral load below limits of quantification (HIV) <sup>5</sup>
3503F	HIV RNA viral load not below limits of quantification (HIV) <sup>5</sup>
3510F	Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) <sup>5</sup>
3511F	Chlamydia and gonorrhea screenings documented as performed (HIV) <sup>5</sup>
3512F	Syphilis screening documented as performed (HIV) <sup>5</sup>
3513F	Hepatitis B screening documented as performed (HIV) <sup>5</sup>
3514F	Hepatitis C screening documented as performed (HIV) <sup>5</sup>
3515F	Patient has documented immunity to Hepatitis C (HIV) <sup>5</sup>
3550F	Low risk for thromboembolism (AFIB) <sup>1</sup>
3551F	Intermediate risk for thromboembolism (AFIB) <sup>1</sup>
3552F	High risk for thromboembolism (AFIB) <sup>1</sup>
3555F	Patient had International Normalized Ratio (INR) measurement performed (AFIB) <sup>1</sup>
3570F	Final report for bone scintigraphy study includes correlation with existing relevant imaging studies (eg, x-ray, MRI, CT) corresponding to the same anatomical region in question (NUC_MED) <sup>1</sup>
3572F	Patient considered to be potentially at risk for fracture in a weight-bearing site (NUC_MED) <sup>1</sup>
3573F	Patient not considered to be potentially at risk for fracture in a weight-bearing site (NUC_MED) <sup>1</sup>
4148F	Hepatitis A vaccine injection administered or previously received (HEP-C) <sup>1</sup>
4149F	Hepatitis B vaccine injection administered or previously received (HEP-C) <sup>1</sup>
4270F	Patient receiving potent antiretroviral therapy for 6 months or longer (HIV) <sup>5</sup>
4271F	Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV) <sup>5</sup>
4274F	Influenza immunization administered or previously received (HIV) <sup>5</sup>
4275F	Hepatitis B vaccine injection administered or previously received (HIV) <sup>5</sup>
4290F	Patient screened for injection drug use (HIV) <sup>5</sup>
4293F	Patient screened for high-risk sexual behavior (HIV) <sup>5</sup>
4300F	Patient receiving warfarin therapy for nonvalvular atrial fibrillation or atrial flutter (AFIB) <sup>1</sup>
4301F	Patient not receiving warfarin therapy for nonvalvular atrial fibrillation or atrial flutter (AFIB) <sup>1</sup>
4320F	Patient counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence (SUD) <sup>5</sup>
5020F	Treatment summary report communicated to physician(s) managing continuing care and to the patient* within one month of completing treatment (ONC)

**REVISED CODE:**

G0248	Demonstration, <u>prior</u> to initial use, of home INR monitoring for patient with <u>either</u> mechanical heart valve(s), <u>chronic atrial fibrillation</u> , or <u>venous thromboembolism</u> who meets Medicare coverage criteria, under the direction of a physician; includes: <u>face-to-face demonstrating</u> <del>demonstration</del> of use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for reporting home INR test results, and documentation of patient ability to perform <del>test</del> <u>testing prior to its use</u> . <b>Revision effective March 1, 2008</b>
G0249	Provision of test materials and equipment for home INR monitoring of patient with <u>either</u> mechanical heart valve(s), <u>chronic atrial fibrillation</u> , or <u>venous thromboembolism</u> who meets Medicare coverage criteria; includes provision of materials for use in the home and reporting of test results to physician; <del>per 4 tests</del> <u>not occurring more frequently than once a week</u> . <b>Revision effective March 1, 2008</b>
G0250	Physician review, interpretation, and patient management of home INR testing for a patient with <u>either</u> mechanical heart valve(s), <u>chronic atrial fibrillation</u> , or <u>venous thromboembolism</u> who meets <u>Medicare</u> <del>other</del> coverage criteria; <del>per 4 tests</del> <u>(does not require face to face services)</u> includes face-to-face verification by the physician that the patient uses the device in the context of the management of the anticoagulation therapy following initiation of the home INR monitoring; <u>not occurring more frequently than once a week</u> . <b>Revision effective March 1, 2008</b>
S0088	Imatinib <del>injection</del> , 100 mg
4158F	Patient <u>counseled about</u> <del>education regarding</del> risks of alcohol <u>use*</u> <del>consumption performed</del> (HEP-C) <sup>1</sup>
4180F	Adjuvant chemotherapy <u>referred*</u> , prescribed, or previously received for Stage III <del>Stage IIIA through Stage IIIC</del> colon cancer (ONC) <sup>1</sup>
4200F	External beam radiotherapy <u>as primary therapy to the prostate</u> <del>only</del> <u>with or without nodal irradiation*</u> (PRCA)
4201F	External beam radiotherapy <u>with or without nodal irradiation as adjuvant or salvage therapy</u> for prostate cancer <u>patient*</u> <del>to region(s) other than prostate only</del> (PRCA) <sup>1</sup>
4250F	Active warming used intraoperatively for the purpose of maintaining normothermia, OR at least one body temperature equal to or greater than 36 degrees Centigrade (or 96.8 degrees Fahrenheit) recorded within the 30 minutes immediately before or the <u>15*</u> minutes immediately after anesthesia end time (CRIT) <sup>1</sup>

**DISCONTINUED CODES:**

S0141	Zalcitabine (ddC), 0.375 mg
3302F	AJCC Cancer Stage 0, documented (ONC)1, (ML)5*
3303F	AJCC Cancer Stage IA, documented (ONC)1, (ML)5*
3304F	AJCC Cancer Stage IB, documented (ONC)1, (ML)5*
3305F	AJCC Cancer Stage IC, documented (ONC)1, (ML)5*
3306F	AJCC Cancer Stage IIA, documented (ONC)1, (ML)5*
3307F	AJCC Cancer Stage IIB, documented (ONC)1, (ML)5*
3308F	AJCC Cancer Stage IIC, documented (ONC)1, (ML)5*
3309F	AJCC Cancer Stage IIIA, documented (ONC)1, (ML)5*
3310F	AJCC Cancer Stage IIIB, documented (ONC)1, (ML)5*
3311F	AJCC Cancer Stage IIIC, documented (ONC)1, (ML)5*
3312F	AJCC Cancer Stage IVA, documented (ONC)1, (ML)5*
3313F	AJCC Cancer Stage IVB, documented (ONC)1, (ML)5*
3314F	AJCC Cancer Stage IVC, documented (ONC)1, (ML)5*
4152F	Documentation that combination peginterferon and ribavirin therapy considered (HEP-C) 1*
4154F	Hepatitis A vaccine series recommended (HEP-C)1*
4156F	Hepatitis B vaccine series recommended (HEP-C)1*

CPT codes copyright 2008 American Medical Association. All Rights Reserved. CPT is a trademark of the AMA.

\*HCPCS stands for Health Care Procedure Coding System.